Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of 9 Meters Biopharma, Inc. (INNT) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of 9 Meters Biopharma, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1551986.
Total stock buying since 2016: $2,192,708.
Total stock sales since 2016: $20,943,975.
Total stock option exercises since 2016: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 9,100 | $11,011 | 0 | $0 |
| 2022 | 658,832 | $257,033 | 0 | $0 | 0 | $0 |
| 2021 | 726,529 | $760,769 | 17,150,781 | $20,932,964 | 0 | $0 |
| 2020 | 861,689 | $552,012 | 0 | $0 | 0 | $0 |
| 2019 | 16,000 | $20,594 | 0 | $0 | 0 | $0 |
| 2018 | 317,559 | $165,029 | 0 | $0 | 0 | $0 |
| 2017 | 608,573 | $369,771 | 0 | $0 | 0 | $0 |
| 2016 | 15,000 | $67,500 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-04 | 0 | $0 | 9,100 | $11,011 | 0 | $0 |
| 2022-07 | 300,000 | $71,550 | 0 | $0 | 0 | $0 |
| 2022-05 | 172,383 | $79,916 | 0 | $0 | 0 | $0 |
| 2022-03 | 186,449 | $105,567 | 0 | $0 | 0 | $0 |
| 2021-12 | 50,000 | $44,500 | 0 | $0 | 0 | $0 |
| 2021-11 | 70,000 | $73,700 | 0 | $0 | 0 | $0 |
| 2021-09 | 88,529 | $118,299 | 0 | $0 | 0 | $0 |
| 2021-08 | 68,000 | $74,270 | 0 | $0 | 0 | $0 |
| 2021-06 | 0 | $0 | 17,150,781 | $20,932,964 | 0 | $0 |
| 2021-04 | 450,000 | $450,000 | 0 | $0 | 0 | $0 |
| 2020-12 | 446,153 | $289,997 | 0 | $0 | 0 | $0 |
| 2020-09 | 148,485 | $95,591 | 0 | $0 | 0 | $0 |
| 2020-08 | 239,108 | $149,725 | 0 | $0 | 0 | $0 |
| 2020-06 | 27,943 | $16,699 | 0 | $0 | 0 | $0 |
| 2019-06 | 5,000 | $5,815 | 0 | $0 | 0 | $0 |
| 2019-05 | 11,000 | $14,779 | 0 | $0 | 0 | $0 |
| 2018-11 | 12,400 | $32,987 | 0 | $0 | 0 | $0 |
| 2018-09 | 1,200 | $7,279 | 0 | $0 | 0 | $0 |
| 2018-08 | 3,959 | $19,763 | 0 | $0 | 0 | $0 |
| 2018-01 | 300,000 | $105,000 | 0 | $0 | 0 | $0 |
| 2017-11 | 366,159 | $164,771 | 0 | $0 | 0 | $0 |
| 2017-06 | 172,414 | $100,000 | 0 | $0 | 0 | $0 |
| 2017-03 | 70,000 | $105,000 | 0 | $0 | 0 | $0 |
| 2016-07 | 15,000 | $67,500 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-04-21 | Sensenig Bethany (Chief Financial Officer) | Sale | 9,100 | 1.21 | 11,011 |
| 2022-07-06 | Temperato John (Chief Executive Officer) | Buy | 125,000 | .23 | 28,500 |
| 2022-07-01 | Sirgo Mark A | Buy | 175,000 | .25 | 43,050 |
| 2022-05-23 | Constantino Michael T. (Director) | Buy | 16,000 | .48 | 7,616 |
| 2022-05-18 | Temperato John (Chief Executive Officer) | Buy | 50,000 | .45 | 22,300 |
| 2022-05-18 | Sirgo Mark A (Director) | Buy | 106,383 | .47 | 50,000 |
| 2022-03-03 | Temperato John (Chief Executive Officer) | Buy | 100,000 | .56 | 55,600 |
| 2022-03-03 | Sirgo Mark A | Buy | 86,449 | .58 | 49,967 |
| 2021-12-02 | Sirgo Mark A (Director) | Buy | 50,000 | .89 | 44,500 |
| 2021-11-18 | Temperato John (Chief Executive Officer) | Buy | 50,000 | 1.05 | 52,500 |
| 2021-11-18 | Sirgo Mark A | Buy | 20,000 | 1.06 | 21,200 |
| 2021-09-14 | Sitar Edward J (Chief Financial Officer) | Buy | 15,000 | 1.22 | 18,300 |
| 2021-09-07 | Sirgo Mark A | Buy | 73,529 | 1.36 | 99,999 |
| 2021-08-24 | Constantino Michael T. | Buy | 18,000 | 1.14 | 20,520 |
| 2021-08-20 | Sirgo Mark A | Buy | 25,000 | 1.10 | 27,500 |
| 2021-08-18 | Temperato John (Chief Executive Officer) | Buy | 25,000 | 1.05 | 26,250 |
| 2021-06-25 | Orbimed Israel Biofund Gp Limited Partnership | Sale | 15,989,876 | 1.21 | 19,347,749 |
| 2021-06-24 | Orbimed Israel Biofund Gp Limited Partnership | Sale | 319,255 | 1.38 | 440,571 |
| 2021-06-23 | Orbimed Israel Biofund Gp Limited Partnership | Sale | 841,650 | 1.36 | 1,144,644 |
| 2021-04-05 | Temperato John (Chief Executive Officer) | Buy | 100,000 | 1.00 | 100,000 |
| 2021-04-05 | Sitar Edward J (Chief Financial Officer) | Buy | 50,000 | 1.00 | 50,000 |
| 2021-04-05 | Sirgo Mark A | Buy | 300,000 | 1.00 | 300,000 |
| 2020-12-15 | Temperato John (Chief Executive Officer) | Buy | 153,846 | .65 | 99,999 |
| 2020-12-15 | Sitar Edward J (Chief Financial Officer) | Buy | 61,538 | .65 | 39,999 |
| 2020-12-15 | Sirgo Mark A | Buy | 230,769 | .65 | 149,999 |
| 2020-09-11 | Sirgo Mark A | Buy | 98,485 | .67 | 65,591 |
| 2020-09-10 | Sirgo Mark A | Buy | 50,000 | .60 | 30,000 |
| 2020-08-21 | Temperato John (Chief Executive Officer) | Buy | 70,000 | .69 | 48,299 |
| 2020-08-20 | Constantino Michael T. | Buy | 34,108 | .75 | 25,581 |
| 2020-08-17 | Temperato John (Chief Executive Officer) | Buy | 35,000 | .57 | 19,845 |
| 2020-08-17 | Sirgo Mark A | Buy | 100,000 | .56 | 56,000 |
| 2020-06-15 | Temperato John (Chief Executive Officer) | Buy | 10,000 | .60 | 5,970 |
| 2020-06-15 | Sirgo Mark A | Buy | 17,943 | .60 | 10,729 |
| 2019-06-28 | Laumas Sandeep (CEO, Executive Chairman) | Buy | 4,000 | 1.15 | 4,600 |
| 2019-06-13 | Laumas Sandeep (CEO, Executive Chairman) | Buy | 1,000 | 1.22 | 1,215 |
| 2019-05-30 | Madan Jay P. (President) | Buy | 5,000 | 1.32 | 6,600 |
| 2019-05-24 | Proujansky Roy | Buy | 1,000 | 1.28 | 1,280 |
| 2019-05-22 | Laumas Sandeep (CEO, Executive Chairman) | Buy | 5,000 | 1.38 | 6,899 |
| 2018-11-30 | Proujansky Roy | Buy | 1,400 | 2.63 | 3,682 |
| 2018-11-30 | Laumas Sandeep (Executive Chairman) | Buy | 3,000 | 2.63 | 7,890 |
| 2018-11-29 | Prior Christopher P. (Chief Executive Officer) | Buy | 5,000 | 2.75 | 13,750 |
| 2018-11-29 | Laumas Sandeep (Executive Chairman) | Buy | 3,000 | 2.56 | 7,665 |
| 2018-09-14 | Prior Christopher P. (Chief Executive Officer) | Buy | 200 | 5.82 | 1,164 |
| 2018-09-12 | Prior Christopher P. (Chief Executive Officer) | Buy | 500 | 6.13 | 3,065 |
| 2018-09-07 | Laumas Sandeep (Executive Chairman) | Buy | 500 | 6.10 | 3,050 |
| 2018-08-30 | Prior Christopher P. (Chief Executive Officer) | Buy | 309 | 5.20 | 1,606 |
| 2018-08-30 | Laumas Sandeep (Executive Chairman) | Buy | 500 | 5.24 | 2,620 |
| 2018-08-28 | Prior Christopher P. (Chief Executive Officer) | Buy | 1,000 | 4.93 | 4,930 |
| 2018-08-28 | Laumas Sandeep (Executive Chairman) | Buy | 750 | 4.98 | 3,737 |
| 2018-08-27 | Almenoff June Sherie (COO and Chief Medical Officer) | Buy | 400 | 4.93 | 1,973 |
| 2018-08-24 | Almenoff June Sherie (COO and Chief Medical Officer) | Buy | 1,000 | 4.90 | 4,897 |
| 2018-01-26 | Clarke David H (Former CEO and Director) | Buy | 300,000 | .35 | 105,000 |
| 2017-11-29 | Clarke David H (Former CEO and Director) | Buy | 366,159 | .45 | 164,771 |
| 2017-06-23 | Clarke David H (Former CEO and Director) | Buy | 172,414 | .58 | 100,000 |
| 2017-03-16 | Clarke David H (Former CEO and Director) | Buy | 70,000 | 1.50 | 105,000 |
| 2016-07-13 | Clarke David H (Former CEO and Director) | Buy | 15,000 | 4.50 | 67,500 |
Insider trading activities including stock purchases, stock sales, and option exercises of INNT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of 9 Meters Biopharma, Inc. (symbol INNT, CIK number 1551986) see the Securities and Exchange Commission (SEC) website.